Marco Rauland
Marco Rauland has more than 20 years of drug development, marketing, market research and pricing consulting experience in the pharmaceutical industry. Prior to joining Merck Marco was Vice President Europe of GfK's Market Access practice. Before that Marco was the global head of the pricing, access and reimbursement practice of Genactis and Senior director of the pricing and reimbursement business unit at TNS Healthcare (now Kantar Group).
Marco is an expert in global pricing, listing and reimbursement strategy and has extensive experience in implementing pricing, access and reimbursement solutions at all stages of the product life cycle, from early product development to post-launch pricing strategies. He has developed the pricing, access and reimbursement strategy for product launches across numerous therapy areas and has in-depth knowledge of international country pricing & reimbursement systems. Marco studied Biochemistry and Pharmacology at the University of Cologne and holds a PhD in Natural Science.
Articles: Marco Rauland
Betting the Bottom Dollar on AI in Pricing & Market Access
Global / Merck KGaA’s Marco Rauland and Kaushal Kishore examine how artificial intelligence and machine learning can best be applied in pharmaceutical pricing and market access. Noting the significant uptake of such tools in other aspects of the pharma value chain, Rauland and Kishore speculate how they might come to revolutionise pricing and market access while cautioning…
Drug Price Prediction: Where Do Machine Learning and AI Stand?
Global / Merck Group’s Vice President Global Market Access & Pricing Strategic Planning, Marco Rauland, takes a look at recent advancements in Machine Learning and Artificial Intelligence and how these technologies can offer a sophisticated and flexible approach not only to predicting drug pricing, but also to estimating market access with different pricing scenarios. Over the…
Are You Smart Enough? Blockchain & Smart Contract Applications in Pharma
Global / Merck Group’s Vice President Global Market Access & Pricing Strategic Planning Marco Rauland casts his eye over blockchain-based smart contracts and their applications for pharma across supply chain enhancement, improving clinical trials, and outcome-based contracting. Smart contracts are self-executing digital contracts based on blockchain technology that provides decentralized data access to the patients and…
Sustainability & Pharma Procurement in Europe: Are You ‘Green’ Enough?
Europe / In the wake of the 2021 United Nations Climate Change Conference (COP26), sustainability is once more a hot-button issue across all industries, including pharma. Here, Marco Rauland, vice president global market access & pricing strategic planning at Merck Group, casts his eye across Europe to assess how sustainability criteria are being integrated into the drug…
Five Ways That AI Can Transform Pharma Market Access
Global / Merck VP for Global Market Access & Pricing Strategic Planning Marco Rauland outlines how AI has already begun to transform pharmaceutical strategy and highlights five ways in which it can be better utilised in pricing and market access decision making. Artificial intelligence (AI) has been creating a buzz in the pharma industry for quite…
Cross Country Collaborations in Europe: The Future of Pricing & Access Negotiations?
Europe / Merck VP for Global Market Access & Pricing Strategic Planning Marco Rauland examines the trend of collaboration between European countries looking to pool their resources on HTA, procurement, pricing, and reimbursement. Rauland compares the five most advanced such collaboration agreements currently active in Europe and the challenges and opportunities inherent in such initiatives. In…
Latest Report
